Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
On Monday, Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating on TriSalus Life Sciences, Inc. (NASDAQ:TLSI) with a steady price target of $9.00. The affirmation follows TriSalus’s announcement on Sunday of its first-quarter financial performance for 2025, along with an update on its business outlook and a recent successful fundraising effort. According to InvestingPro data, analyst targets for TLSI range from $9 to $16, with the company currently maintaining a "Fair" financial health score.
TriSalus reported first-quarter revenues of $9.2 million, which reflects approximately a 42% year-over-year growth. This figure slightly missed Cantor Fitzgerald’s projection of $9.5 million but surpassed the FactSet consensus estimate of $9.0 million. The revenue increase was primarily attributed to the heightened utilization of the company’s TriNav system, which accounted for the entirety of the company’s revenue during the quarter. InvestingPro data shows the company’s impressive trailing twelve-month revenue growth of 46.2%, though it’s worth noting that the company is currently burning through cash rapidly.
The company also experienced a significant expansion of its customer base, with a 39% increase in ordering accounts year-over-year. This growth was marked by the addition of 32 new accounts in the first quarter. Despite this positive development, TriSalus reported a slight contraction in gross margin, which fell by 100 basis points year-over-year to approximately 84%. The margin decline was linked to reduced product output, a consequence of the expansion of the company’s clean-room facilities. The expansion project was completed between the end of February and early March. InvestingPro analysis reveals the company maintains strong liquidity with a current ratio of 2.14, indicating solid short-term financial stability despite ongoing operational investments.
According to Osborn, the gross margin is expected to improve over the course of the year, with projections indicating a rise to the mid-to-high 80s percentage range. Additionally, TriSalus successfully raised $22.0 million in gross proceeds through a private placement, which is expected to bolster the company’s financial position and support its operational objectives moving forward. For deeper insights into TLSI’s financial health, growth prospects, and expert analysis, investors can access the comprehensive Pro Research Report available exclusively on InvestingPro, which covers over 1,400 US stocks with detailed metrics and actionable intelligence.
In other recent news, TriSalus Life Sciences reported a significant 42% year-over-year increase in net sales for Q1 2025, reaching $9.2 million. The company also managed to reduce its operating losses to $7.3 million, down from $11.7 million the previous year, despite a slight decline in gross margin from 85% to 84%. TriSalus projects at least 50% revenue growth in 2025, driven by new product launches and market expansion. The company has been actively expanding its market share, achieving a 10% share in liver procedures and making progress in clinical applications. Additionally, TriSalus raised $22 million in gross proceeds through a private placement, enhancing its financial position. The company plans to invest in expanding its sales force and developing new clinical applications, although it does not anticipate achieving EBITDA or cash flow positivity until early 2026. TriSalus is also seeking to establish pharmaceutical partnerships for its drug nalatolimod, which has shown promising results in clinical trials. These developments reflect the company’s strategic focus on growth and market penetration in the competitive interventional oncology space.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.